Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp., a key player in psychiatric medicine, has announced a private placement to issue listed securities aiming to raise up to CAD$200,000. The funds will support their ongoing Phase 2B trials, expected to complete in 2025, marking a significant step towards enhancing mental health treatments.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
